CHADS2 Score as a Predictor for Platelets Reactivity in Acute Coronary Syndrome

Background:
High on-treatment platelet reactivity is associated with a higher risk for stent thrombosis and acute myocardial infarction following percutaneous coronary interventions (PCI) in acute coronary syndrome (ACS) patients. To the best of our knowledge, no clinical risk score has been evaluated for prediction of platelets reactivity.

Aim:
To evaluate CHADS2 score as a predictor for platelets reactivity in ACS patients receiving P2Y12 receptor inhibitors drugs.

Methods:
Three hundred and fifty-six consecutive ACS patients who underwent PCI and treated with clopidogrel were tested for platelets reactivity using adenosine diphosphate (ADP)-induced aggregation. CHADS2 score was calculated for each patient on a scale of 0-6 and compared with platelet reactivity.

Results:
Patients with a high CAHDS2 score (4-6) had a higher mean of ADP induced aggregation in compared with patients with a low CHADS2 score (0-3) (53 ± 14 vs. 45 ± 17, respectively, p=0.002). Moreover, within the low CHADS2 score group, CHADS2 of 2-3 correlate with higher ADP induced aggregation as compare with CHADS2 0-1 (42 ± 17 vs. 48.5 ± 16, respectively, p<0.001).

Conclusions:
High CHADS2 score is assosiated with high on treatment platelet reactivity.